FAQ/Help |
Calendar |
Search |
Today's Posts |
|
![]() |
#1 | |||
|
||||
In Remembrance
|
1: J Neurol Neurosurg Psychiatry. 2007 Oct 26 [Epub ahead of print]
Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. York MK, Dulay M, Macias A, Levin H, Grossman R, Simpson R, Jankovic J. Baylor College of Medicine, United States. BACKGROUND: We investigated the cognitive and psychiatric outcome 6-months after bilateral subthalamic nucleus deep brain stimulation (DBS) for the treatment of Parkinson's disease (PD) using a disease control group. METHODS: Twenty-three DBS patients were compared to 28 medically-treated PD patients at baseline and 6-months on neuropsychological measures. In addition to the group outcomes, we report reliable change indices (RCI) and a dementia caseness analysis. RESULTS: The DBS patients demonstrated a significant decline in verbal memory compared to the control group (p < 0.003), and trends for decline on oral information processing, including verbal fluency, timed transcription, and word naming. DBS patients demonstrated declines in attention, set shifting, and semantic fluency, however, these changes were similar to the PD groups' rate of decline. RCI indicated that DBS patients demonstrated clinically significant declines in verbal fluency (p <0.01) and inhibition of a dominant response (p <0.003), with trends for declines in set shifting (p<0.02) and verbal long-term recall (p <0.08), indicative of frontostriatal dysfunction. DBS patients did not demonstrate significant changes in depression, anxiety, or psychological distress scores. The caseness analysis revealed that one of the DBS patients (4%) converted to dementia over 6-months compared to none of the PD controls. CONCLUSIONS: Our findings demonstrate that DBS patients experience declines in verbal recall and trends for declines in oral information processing 6-months following surgery even when good motor outcome is achieved. Potential candidates should be counseled about the risk of mild frontostriatal cognitive declines following DBS to weigh the risks and benefits of the surgery. PMID: 17965146 [PubMed - as supplied by publisher]
__________________
Born in 1953, 1st symptoms and misdiagnosed as essential tremor in 1992. Dx with PD in 2000. Currently (2011) taking 200/50 Sinemet CR 8 times a day + 10/100 Sinemet 3 times a day. Functional 90% of waking day but fragile. Failure at exercise but still trying. Constantly experimenting. Beta blocker and ACE inhibitor at present. Currently (01/2013) taking ldopa/carbadopa 200/50 CR six times a day + 10/100 form 3 times daily. Functional 90% of day. Update 04/2013: L/C 200/50 8x; Beta Blocker; ACE Inhib; Ginger; Turmeric; Creatine; Magnesium; Potassium. Doing well. |
|||
![]() |
![]() |
![]() |
#2 | |||
|
||||
Member
|
I have noted this phenomenon, primarily trying to think of words when posting etc. I have noted a decrease in my ability to spell too.
This is nothing I cannot overcome, it just means that I have to stop for a few seconds and think about what i want to say. I'd rather do that then be akinetic on my right side! There is always a "price to pay", albeit a manageable one in this instance. Charlie |
|||
![]() |
![]() |
Reply |
Thread Tools | |
Display Modes | |
|
|
![]() |
||||
Thread | Forum | |||
Study Of Relationship Between Statins And Cognitive Decline | Parkinson's Disease | |||
Celiac Disease and Cognitive Decline | Alzheimer's Disease | |||
Celiac and cognitive decline | Gluten Sensitivity / Celiac Disease |